Sonoma Pharmaceuticals has received regulatory approval from the UK's Medicines & Healthcare products Regulatory Agency (MHRA) for its hypochlorous acid-based acne treatment products. The company announced on April 22, 2025, that these products will be distributed through a prominent health and beauty retailer with over 1,200 stores across the United Kingdom.
The newly approved product line includes an acne toner and a balancing serum, both formulated with Sonoma's patented Microcyn technology. These products will be marketed under the retailer's own brand name, expanding Sonoma's presence in the European dermatological market.
"We are excited to bring our safe and effective acne line to consumers in the United Kingdom and to expand our range of distribution in Europe," said Amy Trombly, CEO of Sonoma Pharmaceuticals. "These products utilize all-natural hypochlorous acid and our patented Microcyn technology formulation, providing a safe and gentle alternative to products containing harsh ingredients such as alcohol and benzoyl peroxide."
Innovative Technology for Acne Treatment
Sonoma's acne products are based on stabilized hypochlorous acid (HOCl), a naturally occurring molecule with antimicrobial properties. The company's proprietary Microcyn technology creates a stable formulation of HOCl that has demonstrated efficacy in managing various skin conditions.
Clinical studies have shown that Sonoma's HOCl formulations can effectively reduce itch, pain, scarring, and irritation without damaging healthy tissue. This makes them particularly suitable for acne treatment, where skin sensitivity is often a concern with traditional therapies.
The gentle nature of these products addresses a significant unmet need in the acne treatment market, where many conventional treatments can cause dryness, redness, and irritation. By offering a milder alternative that maintains efficacy, Sonoma aims to improve treatment adherence and outcomes for acne sufferers.
Market Expansion Strategy
This UK product registration represents a significant step in Sonoma's international growth strategy. The company currently sells its products in 55 countries worldwide, either directly or through distribution partners.
The partnership with a major UK pharmacy chain provides Sonoma with immediate access to a broad consumer base. By leveraging the retailer's established brand and extensive store network, Sonoma can rapidly introduce its innovative acne solutions to the British market.
Sonoma's European operations are headquartered in Roermond, Netherlands, positioning the company to efficiently support this UK market entry and potential future expansions across Europe.
Broader Applications of Microcyn Technology
Beyond acne treatment, Sonoma's HOCl-based products address a wide range of applications, including wound care, eye care, oral and nasal care, and other dermatological conditions. The company also produces formulations for podiatry, animal health care, and non-toxic disinfection.
The versatility of Sonoma's technology platform allows the company to target multiple market segments with variations of its core HOCl formulation. This diversified approach helps mitigate market risks while maximizing the commercial potential of their proprietary technology.
Company Background
Sonoma Pharmaceuticals, headquartered in Boulder, Colorado, operates manufacturing facilities in Guadalajara, Mexico. The company is publicly traded on the Nasdaq under the ticker symbol SNOA.
The company's focus on developing safe, effective alternatives to traditional treatments has positioned it as an innovator in the field of hypochlorous acid applications. As consumer demand for gentler, more natural skincare solutions continues to grow, Sonoma's technology platform offers significant potential for addressing evolving market needs.
